Characteristics | n (%) |
---|---|
Total patients included | 216 (100) |
Age at time of diagnosis (y) | 69.6 (61.1; 74.1) a |
Sex | |
 Male | 186 (86.1) |
 Female | 30 (13.9) |
Etiology of liver disease | |
 Alcohol | 96 (44.4) |
 Viral hepatitis | 53 (24.6) |
 NASH | 18 (8.3) |
 Cryptogenic | 14 (6.5) |
 No liver disease | 29 (13.4) |
 Other | 6 (2.8) |
Cirrhosis | |
 Yes | 173 (80.1) |
 No | 43 (19.9) |
BCLC stage | |
 BCLC 0 | 0 |
 BCLC A | 36 (16.7) |
 BCLC B | 25 (11.6) |
 BCLC C | 111 (51.4) |
 BCLC D | 44 (20.4) |
Tumor grading | |
 Well | 41 (19) |
 Moderate | 75 (34.7) |
 Poor | 38 (17.6) |
 Missing | 62 (28.7) |
Tumor size | |
  ≤ 2 cm | 15 (6.9) |
 2–5 cm | 78 (36.1) |
  > 5 cm | 82 (38) |
 Missing | 41 (19) |
Tumor nodularity | |
 Solitary | 56 (25.9) |
 Multifocal | 108 (50) |
 Missing | 52 (24.1) |
Metastasis | |
 Lymph nodes | 19 (8.8) |
 Distant | 24 (11.1) |
 Missing | 173 (80.1) |
Intrahepatic vascular invasion | 64 (29.6) |
Primary therapy | |
 TACE | 87 (40.3) |
 Resection | 27 (12.5) |
 Liver transplantation | 5 (2.3) |
 Sorafenib | 44 (20.4) |
 Best supportive care | 46 (21.3) |
 Others (SIRT, RFA) | 7 (3.2) |
Serum α-FP (ng/mL) | 46.5 (7.2; 1188.3) a |
MELD | 10 (7; 13) a |
Serum IGF-1 | 43.4 (27.7; 68.6) a |
Overall survival (months) | 11.38 (4.6; 33.2) a |